Autonomix Medical, Inc. (NASDAQ:AMIX) Stock Short Interest Falls 56.3%

Autonomix Medical, Inc. (NASDAQ:AMIX – Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 26,830 shares, a drop of 56.3% from the September 15th total of 61,425 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average trading volume of 114,154 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AMIX shares. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Autonomix Medical presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Get Autonomix Medical alerts:

View Our Latest Research Report on AMIX

Autonomix Medical Stock Down 0.8%

Shares of AMIX traded down $0.03 during midday trading on Wednesday, reaching $2.98. 21,504 shares of the stock were exchanged, compared to its average volume of 1,490,657. Autonomix Medical has a twelve month low of $2.44 and a twelve month high of $32.55. The company has a market cap of $2.90 million, a P/E ratio of -0.07 and a beta of -0.96. The stock’s 50 day simple moving average is $5.24 and its 200 day simple moving average is $6.53.

Autonomix Medical (NASDAQ:AMIX – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. As a group, analysts predict that Autonomix Medical will post -20.17 earnings per share for the current year.

About Autonomix Medical

(Get Free Report)

Autonomix Medical, Inc is a clinical-stage medical device company developing catheter-based technologies for the diagnosis and treatment of conditions involving the peripheral and autonomic nervous systems. Its platform is designed to help physicians identify and access nerves during minimally invasive procedures.

The company’s technology incorporates a miniature sensor into a catheter to detect neural signals in real time. Autonomix is initially focused on applications in pain management, including procedures intended to treat pain associated with pancreatic cancer, while also evaluating broader uses in chronic pain and other conditions involving abnormal nerve activity.

Autonomix Medical’s products are in the development and clinical-evaluation stages, and the company’s technology may require additional testing, regulatory review and approval before broader commercialization.

See Also

• Five stocks we like better than Autonomix Medical
• High Voltage Returns: Navitas Rewires AI Data Centers
• Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
• Albertsons Is Betting on a Turnaround—But Will It Pay Off?
• Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit

Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.